Clinical trial
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating…
NCT00055887 · Spectrum Pharmaceuticals, Inc, Industry · Withdrawn
Key facts
| NCT number | NCT00055887 |
|---|---|
| Title | Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer |
| Official title | A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | carboplatin, cisplatin, efaproxiral, gemcitabine hydrochloride, paclitaxel, vinorelbine ditartrate, radiation therapy |
| Enrollment | 0 |
| Start date | Nov 1, 2002 |
| First posted | Mar 7, 2003 |
| Last update posted | May 10, 2013 |
| Countries | Belgium, Canada, Israel, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: